HCA Healthcare Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Results

Benzinga Earnings10-28 21:24

HCA Healthcare Inc. (NYSE:HCA) on Tuesday posted upbeat third-quarter results.

The company posted quarterly revenues of $19.849 billion, representing a 3.6% year-over-year increase, beating the consensus estimate of $19.332 billion. The company reported adjusted earnings of $7.22, up from $6.96 a year ago, surpassing the Wall Street estimates of $6.66.

"Despite the challenges brought about by federal policy changes this year, our colleagues have continued to provide high-quality care to patients, and we believe HCA Healthcare is positioned to end the year positively,” said Sam Hazen, CEO of HCA Healthcare.

HCA Healthcare raised fiscal 2026 earnings guidance from $28.70-$30.50 per share to $29.60-$30.50 per share compared to the consensus of $29.46. The company raised its fiscal 2026 sales guidance from $77 billion-$79.50 billion to $78.250 billion-$79.50 billion compared to the consensus of $78.517 billion.

HCA Healthcare shares closed at $449.96 on Tuesday.

These analysts made changes to their price targets on HCA Healthcare following earnings announcement.

B of A Securities analyst Joanna Gajuk maintained the stock with a Neutral and raised the price target from $450 to $500.
Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $393 to $409.
Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and boosted the price target from $435 to $490.

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2678749595?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-28 21:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2678749595","market":"hk","top_or_hot":-1,"title":"HCA Healthcare Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Results","media":"Benzinga Earnings","content":"<html><body><p><strong>HCA Healthcare Inc</strong>. (NYSE:HCA) on Tuesday posted upbeat third-quarter results.</p>\n<p>The company posted quarterly revenues of $19.849 billion, representing a 3.6% year-over-year increase, beating the consensus estimate of $19.332 billion. The company reported adjusted earnings of $7.22, up from $6.96 a year ago, surpassing the Wall Street estimates of $6.66.</p>\n<p>\"Despite the challenges brought about by federal policy changes this year, our colleagues have continued to provide high-quality care to patients, and we believe HCA Healthcare is positioned to end the year positively,” said Sam Hazen, CEO of HCA Healthcare.</p>\n<p>HCA Healthcare raised fiscal 2026 earnings guidance from $28.70-$30.50 per share to $29.60-$30.50 per share compared to the consensus of $29.46. The company raised its fiscal 2026 sales guidance from $77 billion-$79.50 billion to $78.250 billion-$79.50 billion compared to the consensus of $78.517 billion.</p>\n<p>HCA Healthcare shares closed at $449.96 on Tuesday.</p>\n<p>These analysts made changes to their price targets on HCA Healthcare following earnings announcement.</p>\n<ul>\n<li>B of A Securities analyst Joanna Gajuk maintained the stock with a Neutral and raised the price target from $450 to $500.</li>\n<li>Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $393 to $409.</li>\n<li>Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and boosted the price target from $435 to $490.</li>\n</ul>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HCA Healthcare Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHCA Healthcare Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-10-28 21:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>HCA Healthcare Inc</strong>. (NYSE:HCA) on Tuesday posted upbeat third-quarter results.</p>\n<p>The company posted quarterly revenues of $19.849 billion, representing a 3.6% year-over-year increase, beating the consensus estimate of $19.332 billion. The company reported adjusted earnings of $7.22, up from $6.96 a year ago, surpassing the Wall Street estimates of $6.66.</p>\n<p>\"Despite the challenges brought about by federal policy changes this year, our colleagues have continued to provide high-quality care to patients, and we believe HCA Healthcare is positioned to end the year positively,” said Sam Hazen, CEO of HCA Healthcare.</p>\n<p>HCA Healthcare raised fiscal 2026 earnings guidance from $28.70-$30.50 per share to $29.60-$30.50 per share compared to the consensus of $29.46. The company raised its fiscal 2026 sales guidance from $77 billion-$79.50 billion to $78.250 billion-$79.50 billion compared to the consensus of $78.517 billion.</p>\n<p>HCA Healthcare shares closed at $449.96 on Tuesday.</p>\n<p>These analysts made changes to their price targets on HCA Healthcare following earnings announcement.</p>\n<ul>\n<li>B of A Securities analyst Joanna Gajuk maintained the stock with a Neutral and raised the price target from $450 to $500.</li>\n<li>Baird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $393 to $409.</li>\n<li>Keybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and boosted the price target from $435 to $490.</li>\n</ul>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014039.USD","symbol_name":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/10/62654618/hca-healthcare-analysts-raise-their-forecasts-following-better-than-expected-q3-results","article_id":"2678749595","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2678749595","pubTimestamp":1793193892,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"HCA Healthcare beat Q3 estimates: revenue rose 3.6% to $19.85B, EPS hit $7.22, and FY26 guidance increased; analysts raised price targets.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4504":"桥水持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","BK4588":"碎股","XLV":"健康照护类股ETF-SPDR","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","BK4185":"保健护理机构","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","IHF":"iShares Dow Jones U.S. Health Ca","BK4581":"高盛持仓","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","HCA":"HCA控股","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","XBI":"SPDR S&P Biotech ETF","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4585":"ETF&股票定投概念","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LABU":"三倍做多标普生物-Direxion","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC"},"translate_title":"HCA 医疗保健分析师在第三季度业绩好于预期后上调了预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":0.6,"XLV":1.5,"IHF":0.6,"HCA":1.5,"LABU":0.6},"content_text":"HCA Healthcare Inc. (NYSE:HCA) on Tuesday posted upbeat third-quarter results.\nThe company posted quarterly revenues of $19.849 billion, representing a 3.6% year-over-year increase, beating the consensus estimate of $19.332 billion. The company reported adjusted earnings of $7.22, up from $6.96 a year ago, surpassing the Wall Street estimates of $6.66.\n\"Despite the challenges brought about by federal policy changes this year, our colleagues have continued to provide high-quality care to patients, and we believe HCA Healthcare is positioned to end the year positively,” said Sam Hazen, CEO of HCA Healthcare.\nHCA Healthcare raised fiscal 2026 earnings guidance from $28.70-$30.50 per share to $29.60-$30.50 per share compared to the consensus of $29.46. The company raised its fiscal 2026 sales guidance from $77 billion-$79.50 billion to $78.250 billion-$79.50 billion compared to the consensus of $78.517 billion.\nHCA Healthcare shares closed at $449.96 on Tuesday.\nThese analysts made changes to their price targets on HCA Healthcare following earnings announcement.\n\nB of A Securities analyst Joanna Gajuk maintained the stock with a Neutral and raised the price target from $450 to $500.\nBaird analyst Michael Ha maintained the stock with a Neutral and raised the price target from $393 to $409.\nKeybanc analyst Matthew Gillmor maintained the stock with an Overweight rating and boosted the price target from $435 to $490.\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2678749595","isCrawlerRequest":true}